SCHEMBL2363082

SCHEMBL2363082

COc1cc(CN)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.44
CYP3A4 P08684 4/20 0.43
CYP1A1 P04798 1/20 0.38
ERBB2 P04626 1/20 0.36
CD274 Q9NZQ7 1/20 0.35
ALPL P05186 1/20 0.35
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
ADRA2A P08913 1/20 0.32
ADRA2C P18825 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
HTR2C P28335 1/20 0.32
MAPK14 Q16539 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2362488 0.91 HTR2A (0.54) HTR2ACYP3A4CYP1A1HTR2CHTR2B
SCHEMBL2363467 0.88 CYP3A4 (0.43) HTR2ACYP3A4CYP1A1ERBB2CD274
SCHEMBL2364691 0.86 ICMT (0.44) HTR2ACYP3A4CYP1A1ERBB2CD274
SCHEMBL3308904 0.86 CYP3A4 (0.42) HTR2ACYP3A4CYP1A1ERBB2ALPL
SCHEMBL2362428 0.86 CYP3A4 (0.44) HTR2ACYP3A4CYP1A1ERBB2ALPL
SCHEMBL2362843 0.85 CYP3A4 (0.48) HTR2ACYP3A4CYP1A1ERBB2ALPL
SCHEMBL2354510 0.85 CYP3A4 (0.41) HTR2ACYP3A4CYP1A1ERBB2ALPL
SCHEMBL11958301 0.84 CYP3A4 (0.41) HTR2ACYP3A4CYP1A1ERBB2ALPL
SCHEMBL2352735 0.83 CYP3A4 (0.45) HTR2ACYP3A4CYP1A1ERBB2ALPL
SCHEMBL2352880 0.83 CYP3A4 (0.42) HTR2ACYP3A4CYP1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US disclosed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B HTR2A 2942/4885CYP3A4 423/4885CYP1A1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.